Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models

Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed chemotherapy. Using a two-tier phenotypic scree...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Lijuan, Li, Xin, Yang, Yang, Zhao, Rui, White, Elshaddai Z., Danaher, Alira, Bowen, Nathan J., Hinton, Cimona V., Cook, Nicholas, Li, Dehong, Wu, Alyssa Y., Qui, Min, Du, Yuhong, Fu, Haian, Kucuk, Omer, Wu, Daqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248552/
https://www.ncbi.nlm.nih.gov/pubmed/37271121
http://dx.doi.org/10.1016/j.tranon.2023.101707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248552/
https://www.ncbi.nlm.nih.gov/pubmed/37271121
http://dx.doi.org/10.1016/j.tranon.2023.101707

Ejemplares similares